What Artelac Treats: Main Uses and Benefits

The primary role of Artelac (Hypromellose) is generally used to provide support that helps ease the overall symptom burden associated with inadequate tear film. It is commonly used when supportive symptom management is appropriate.

The medication is considered relevant for managing symptom clusters that interfere with daily comfort. It is applied in situations where patients experience discomfort arising from conditions characterized by periods of heightened symptoms such as Dry Eye Disease (DED) and related tear dysfunction. It helps address symptoms related to physical discomfort, such as stinging, burning, irritation, and foreign body sensation.

Artelac assists with maintaining functional stability, which supports general well-being during symptomatic phases.

The medication is often used during phases when symptoms become more noticeable, such as after prolonged screen time or exposure to environmental triggers. This provides supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Focuses on Symptomatic Relief for Stinging and Grittiness

Regulatory References

1. NIH DailyMed Labeling

The official regulatory eligibility for Artelac (Hypromellose) is defined primarily by hypersensitivity and is otherwise broad due to the medicine's topical, non-systemic nature.

Eligibility scope

Eligibility Category	Official Regulatory Statement
Populations for whom use is allowed	Adults, children, and the elderly are explicitly indicated as suitable for use.
Populations for whom use is contraindicated	Patients with known hypersensitivity (allergy) to the active substance, Hypromellose, or to any of the specific excipients in the drops.
Age-related eligibility rules	Use is suitable for all ages, including children, adolescents, and older adults, with no required dosage adjustment based on age alone.
Pregnancy and lactation eligibility status	Use is permitted during pregnancy and lactation as negligible systemic exposure is anticipated.
Eligibility-related restrictions	Soft contact lens wearers must remove their lenses before applying preservative-containing drops and wait a minimum of 15 minutes before re-inserting them.

Eligibility classifications (high-level)

• Eligibility severity classification: Absolute Contraindication (Hypersensitivity) and Conditional Use/Precaution (Soft Contact Lens Wearers).
• Eligibility-context constraints: Constraints are primarily related to Topical Hypersensitivity and ocular device use.

Resulting eligibility structure

Official eligibility statements confirm that Artelac is permitted for use across all major age groups, including pediatric and geriatric populations. The only absolute rule defining non-eligibility is a history of hypersensitivity to the formulation’s components. As an inert, surface-acting preparation, official regulatory documents explicitly permit its use during both pregnancy and lactation, and no restrictions are placed on patients based on systemic conditions like renal or hepatic impairment.

Interactions with other medicines and products

The official interaction profile for Artelac (Hypromellose) is defined by its core property as an inert, non-systemically absorbed ophthalmic solution. This lack of systemic exposure governs the absence of documented chemical interactions with other pharmaceutical products, as confirmed by regulatory authorities.

Systemic Interaction Status

No pharmacokinetic (PK) or pharmacodynamic (PD) interactions with orally or intravenously administered medicines are documented in official regulatory labeling. Artelac is an inert substance and is not absorbed into the body in clinically significant amounts; therefore, it is not documented to affect the metabolism (e.g., CYP enzymes) or clearance of co-administered systemic drugs. Consequently, no exposure-modifying interactions are noted, and no specific systemic drug combinations are formally classified as contraindicated due to interaction risk.

Administration-Timing Constraints

The documented interaction profile relates exclusively to physical constraints on the surface of the eye.

• Topical Ophthalmic Preparations: Co-administration with any other eye drops, ointments, or gels requires a mandatory minimum interval of at least 5 minutes. This requirement prevents the physical dilution of either product and maintains the stability of the protective tear film.
• Soft Contact Lenses: When used in formulations containing the preservative Benzalkonium Chloride, soft contact lenses must be removed before application. Reinsertion should be deferred for at least 15 minutes due to a documented physical incompatibility between the excipient and the lens material.

No specific interactions with food, alcohol, or herbal products are documented in regulatory labeling.

Primary Intracellular Targets

The compound is absorbed and enters the systemic circulation, where it primarily targets T-lymphocytes. Within these cells, the molecule initiates its action by modulating the intracellular Ca^2+/cAMP signaling balance. This initial interaction represents the core mechanism of action, influencing the cell's internal environment and preparing it for downstream signal regulation.

Downstream Signal Cascades

Modulation of the Ca^2+/cAMP ratio leads to a decreased activation of NF-kappa B signaling, a critical nuclear transcription factor. Concurrently, the molecule functions by directly binding to and inhibiting the COX-2 enzyme (cyclooxygenase-2). This dual-pathway approach ensures broad regulation of cellular responses through two distinct molecular cascades.

Modulation of Osteoclast Lineage

The inhibition of NF-kappa B signaling further contributes to a molecular consequence involving bone regulation. Specifically, the cascade inhibits the binding of RANKL to RANK receptors on pre-osteoclast cells. This action reduces the signaling events responsible for osteoclast differentiation and activity, completing the system-level physiological effect within the biochemical domain.

How to Use Artelac Eye Drops

Artelac (which may contain active ingredients such as hypromellose or sodium hyaluronate) is used as an artificial tear to relieve symptoms of dry eyes, such as soreness or irritation. The medicine is administered directly into the eye (ocular use only).

General Administration Instructions

1. Hand Hygiene: Always wash your hands thoroughly before handling the eye drops.
2. Positioning: Sit down or stand comfortably in front of a mirror to clearly see the eye.
3. Application: Gently pull your lower eyelid down to create a small pocket. Hold the bottle or single-dose unit upside down, and carefully place one drop into the conjunctival sac (the inner corner of the lower eyelid, nearest the nose). Take care to ensure the dropper tip does not touch any surface, including the eye or fingers, to prevent contamination.
4. Distribution: Release the lower eyelid and blink a few times to spread the liquid across the eye's surface.
5. Dose and Frequency: The usual recommended dosage for Artelac containing hypromellose is 1 drop, applied to the affected eye(s) 3 to 5 times per day, or as needed for sufficient lubrication. Consult a healthcare professional to determine the appropriate dosage regimen for your individual condition.

Important Considerations

Situation	Action Required
Soft Contact Lenses	Remove lenses before administration and wait at least 15 minutes before re-inserting them.
Blurred Vision	A temporary blurring of vision may occur upon instillation. Wait until vision has cleared before driving or operating machinery.
Single-Dose Units	Preservative-free single-dose units must be discarded immediately after a single use, even if solution remains.

If irritation persists or worsens, or if new eye symptoms develop, discontinue use and seek medical advice.

Research Evidence / Overview of Studies for Artelac (Hypromellose)

---

Research Evidence for Symptoms of Dry Eye Disease

The research base for Hypromellose (Artelac) is relevant in trials assessing short-term or episodic symptom patterns and includes a mix of Randomized Controlled Trials (RCTs) and comprehensive systematic reviews that have examined various artificial tear preparations. These studies have primarily focused on adults experiencing conditions characterized by fluctuating or episodic manifestations of dry eye. The evidence largely comes from settings where the goal was to describe how symptoms change over defined time intervals, usually covering short durations, with research exploring how symptoms change over time when Hypromellose (Artelac) is the subject of study for ocular dryness.

In these trials, researchers monitored two main types of outcomes. First, studies used patient-reported outcomes describing perceived discomfort to track measurements of changes in feelings like burning, stinging, dryness, and foreign body sensation. Second, research examined objective measures, such as Tear Break-Up Time (TBUT) and corneal staining scores, which are outcomes related to physiological strain or stress on the eye's surface. Findings describe patterns observed in the studies where studies reported measurements of changes in subjective comfort scores. However, the data show patterns related to objective measures that were often observed in some studies but were not consistently demonstrated across the entire evidence landscape.

---

Focus of Clinical Trials: Subjective Comfort vs. Objective Measures

Studies involving Artelac were conducted during periods of increased symptom activity and applied in research contexts involving fluctuating or unstable symptoms. These trials consistently monitored outcomes related to physical discomfort as the primary focus. In many cases, studies focused on collecting data about how patients reported their experience and what changes they perceived in their daily functioning or activity level.

In contrast, outcomes describing episodic or acute changes in objective measures, such as tear film metrics or surface integrity scores, were often observed, but findings were mixed across the diverse research available. This is relevant in trials assessing short-term symptom patterns, where the solution was evaluated for temporary surface lubrication. The evidence contributes to understanding symptom patterns, but the reported outcomes related to physical signs are highly dependent on the specific formulation and study design used.

---

Long-Term Evidence and Follow-Up Duration

The duration of observation is a key factor in the existing research. Many dedicated RCTs exploring short-term symptom changes focused on timeframes of only two to four weeks. While some studies extended observation periods up to 90 days, there is limited information for long-term outcomes and the sustained changes observed when the solution is used.

Because of this, long-term effects are not fully established. The evidence for continuous use relies primarily on the substance’s inclusion in established regulatory monographs and its historical use as an ophthalmic demulcent, and not from multi-year, large-scale controlled trials. The research provides insight into short-term changes, but long-term outcomes are not well characterized, meaning evidence describing how symptoms are measured over years remains insufficient.

---

What Remains Uncertain in the Research Landscape

The evidence highlights what is known and what is still uncertain about Artelac. A key limitation is that evidence quality varies across studies, with many having modest sample sizes. Furthermore, comparative evidence that directly contrasts Hypromellose with newer, high-viscosity artificial tears is sometimes lacking or yields mixed findings, particularly when monitoring objective clinical endpoints.

The follow-up durations were limited across the core trials, contributing to uncertainty regarding the long-term changes observed when the solution is used. Therefore, certainty remains low regarding the long-term sustainability of the observed symptom patterns, and data for long-term outcomes remain insufficient, reflecting the specific conditions under which the studies were conducted.

Key Studies & References Submission for the 2023 Meeting of the WHO Expert Committee on Selection and Use of Essential Medicines (Hypromellose for Dry Eye Disease)

Common questions about Artelac (FAQ)

Q: What are the differences between Artelac Advanced and Artelac Rebalance?

A: Official information indicates that different Artelac formulations contain varying ingredients. For example, Artelac Advanced typically contains Sodium Hyaluronate as a key ingredient. Artelac Rebalance is described as a multi-component formulation, including Sodium Hyaluronate, PEG 8000, electrolytes, and Vitamin B12.

---

Q: Can Artelac be used for non-dry eye conditions, like allergies?

A: The product literature for certain Artelac products indicates they may be used for purposes beyond general dryness. For instance, the official product information for Artelac Protect describes it as being indicated to protect the eye from allergens and to relieve inflammation and irritation.

---

Q: Are there different Artelac products for day and night use?

A: The Artelac product range includes different formulations intended for day and night use. Formulations like Artelac Nighttime Gel are specifically recommended in the instructions to be instilled before going to bed, while other drops are intended for daily use.

---

Q: What is the difference between Artelac drops and the Artelac gel formulation?

A: The primary difference lies in the viscosity of the product. According to official product information, the gel formulation contains ingredients such as carbomer to achieve a much higher viscosity than the drops. This thicker consistency is designed to remain on the ocular surface for a longer duration.

---

Q: Do studies support the long-lasting hydration claims of Artelac Rebalance?

A: Official product information for Artelac Rebalance describes its formulation as being intended to remain on the surface of the eye. The product is designed to provide long-lasting relief and uses components that support the natural tear film structure.

---

Q: How does the carbomer in Artelac Nighttime Gel help with dry eyes overnight?

A: The carbomer component contributes to the gel's high viscosity. The viscosity allows the product to remain on the eye's surface, which is intended to provide long-lasting moisture retention and physical protection throughout the night.

---

Q: What is the role of Vitamin B12 in the Artelac Rebalance formulation?

A: The official product information for Artelac Rebalance indicates that Vitamin B12 is included in the formula as an antioxidant. The inclusion of Vitamin B12 is intended to support the protection of the ocular surface.

---

Q: Can environmental factors like wind or air conditioning affect how Artelac works?

A: Official product information indicates that Artelac is used for dry eye symptoms that are often caused by external factors. These environmental causes specifically include air conditioning, high heat, and exposure to wind, which can contribute to ocular dryness and irritation.

---

Q: Why is the Artelac Nighttime Gel specifically recommended for overnight use?

A: The instructions recommend the Nighttime Gel for use before sleep due to its high viscosity. This quality allows it to provide long-term relief and maximum moisture retention across the eye's surface, making it ideal for the extended duration when the eyes are closed.

---

Q: What type of dry eye is Artelac best suited for: aqueous-deficient or evaporative?

A: Formulations like Artelac Complete are described in clinical summaries as being formulated to manage both aqueous-deficient and lipid-deficient dry eye. This is achieved by combining ingredients intended to target and stabilize different layers of the tear film.

---

Q: Is it normal for my eyes to water more after applying Artelac?

A: Official instructions for certain Artelac products note that their use may be relevant to conditions where the eye exhibits excessive tearing (watery eyes). This suggests the product may be used in the context of symptoms that include increased watering.

---

Q: What does Artelac Nighttime Gel feel like once it is applied to the eye?

A: Due to its thicker gel consistency, the product instructions state that the formulation will likely cause initial blurring upon installation. This effect is temporary, and vision should clear once the user blinks and the gel is distributed across the eye's surface.

---

Q: Does Artelac have a dedicated product for allergy symptoms, and how does it work?

A: The product line includes formulations, such as Artelac Protect, that are indicated for use against allergens. It works by using Ectoin and sodium hyaluronate to help stabilize the eye's natural protective barrier and relieve irritation from allergy triggers.

---

Q: What scientific data supports the effectiveness of Ectoin in Artelac Protect drops?

A: Official product information describes Ectoin as a natural molecule with cell-protective and anti-inflammatory properties. This ingredient is used to support the eye’s barrier function, particularly in the presence of allergens.

How to Store and Dispose of Artelac?

The storage and disposal of Artelac (Hypromellose eye drops) must follow strict regulatory guidelines to maintain product stability and environmental safety.

---

Storage Requirements

Artelac must be stored at a temperature not above 25 C (77°F). All medicine must be kept out of the sight and reach of children.

Container Type	In-Use Stability Limit	Other Rule
Multi-dose bottle	Discard 28 days after first opening	Store protected from light
Single-dose units	Discard immediately after use	Keep in the original outer box

---

Disposal Instructions

Expired or unused Artelac must not be thrown away via wastewater or household waste. Official procedure requires users to ask a pharmacist how to dispose of the medicine. These measures are required to ensure the protection of the environment.